Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $146

Morgan Stanley analyst Ricky Goldwasser maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from $142 to $146.
byBenzinga Newsdesk
October 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Ricky Goldwasser maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from $142 to $146.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY

By Joana Scopel
December 1, 11:17 PM
Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the

BRAXF